Navigation Links
BIO 2008: Germany on Cutting Edge in Biomanufacturing
Date:6/18/2008

SAN DIEGO, California, June 18 /PRNewswire/ -- Germany is on the cutting edge in biotechnology R&D and is a top player in large- and clinical-scale production. Companies located in Germany are poised to profit from the latest developments in biomanufacturing. These were the results of an expert panel, at the BIO International Convention (BIO 2008) in San Diego, California on June 18th. Invest in Germany co-chaired the panel along with the CEO of a major transatlantic biotech consultancy.

Dr. Barbara Esch opened the discussion, entitled "Biomanufacturing Solutions: Case Studies from Germany." She is responsible for the business development of biopharmaceuticals in the Corporate Division Biopharmaceuticals at the Boehringer Ingelheim GmbH in Ingelheim, Germany. Her presentation provided an overview of the biotechnology market in Germany, and offered examples of leading investment successes in Germany. Dr. Wiltrud Treffenfeldt, Director of Bioprocess Development, Dow AgroSciences LLC, discussed why the German contract manufacturing industry is uniquely positioned to create sustainable value in biopharmaceutical development and supply. Dr. Uwe Marx, Chief Scientific Officer (CSO) of Probiogen, a Berlin-based company that specializes in mammalian cell engineering and cell culture, discussed clinical biomanufacturing and how it serves the diverse needs of his company's client base.

Lastly Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius AG, talked about his perception of the current trends in biomanufacturing from the focus of an internationally leading process technology provider.

Angelika Geiger, Director of Invest in Germany's San Francisco office, and Steven Dickman, CEO of CBT Advisors chaired the panel. CBT Advisors is an international strategic consultancy with a focus on European and American biotech companies. Mr. Dickman also has experience in Germany. He previously did biochemical research at the German Cancer Research Center and served as correspondent for the journal Nature in Germany.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. Invest in Germany is at booth 711 throughout BIO 2008.

Eva Henkel

Invest in Germany

Phone: +49-30-200099-173

email: henkel@invest-in-germany.com

http://www.invest-in-germany.com


'/>"/>
SOURCE Invest in Germany
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Commencement 2008: Student innovation could improve data storage, magnetic sensors
3. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
4. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
5. The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
6. Pharmaxis Aridol Authorised for Sale in Germany
7. World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment
8. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
9. Germany Hosts World Leading Medical Industry Fair
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):